Hansa Medical proceeds to releasing financial reports quarterly. The following dates have been scheduled for financial reporting during 2015: Year-end release 2014, February 13, 2015 Annual report 2014, March 2, 2015 Interim report January – March 2015, April 16, 2015 Annual General Meeting 2015, April 16, 2015 Interim report January – June 2015, August 25, 2015 Interim report January – September 2015, October 28, 2015 For further information, please contact: Hansa Medical AB Fredrik Lindgren, President and CEO Mobile: 46 705 61 61 77 E-mail: fredrik.lindgren@hansamedical.com www.hansamedical.com About Hansa Medical AB Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on NASDAQ First North in Stockholm with Remium Nordic AB as Certified Adviser. Major shareholders are Farstorps Gård AB and Nexttobe AB.
Hansa Medical financial reporting dates
| Source: Hansa Medical AB